Reviva Pharmaceuticals Holdings Stock Performance
| RVPHW Stock | USD 0.21 0.04 23.53% |
Reviva Pharmaceuticals holds a performance score of 12 on a scale of zero to a hundred. The company holds a Beta of 0.58, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Reviva Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Reviva Pharmaceuticals is expected to be smaller as well. Use Reviva Pharmaceuticals treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day typical price , to analyze future returns on Reviva Pharmaceuticals.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent technical indicators, Reviva Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - StockTitan | 09/26/2024 |
2 | Reviva to Participate in the UBS Global Healthcare Conference - Yahoo Finance | 10/31/2024 |
3 | ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com | 11/15/2024 |
| Begin Period Cash Flow | 18.5 M |
Reviva |
Reviva Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 9.74 in Reviva Pharmaceuticals Holdings on August 27, 2024 and sell it today you would earn a total of 11.26 from holding Reviva Pharmaceuticals Holdings or generate 115.61% return on investment over 90 days. Reviva Pharmaceuticals Holdings is currently producing 3.0322% returns and takes up 19.7689% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Reviva, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Reviva Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Reviva Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reviva Pharmaceuticals Holdings, and traders can use it to determine the average amount a Reviva Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1534
| Best Portfolio | Best Equity | |||
| Good Returns | RVPHW | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.77 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.03 actual daily | 60 60% of assets have lower returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Reviva Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reviva Pharmaceuticals by adding it to a well-diversified portfolio.
Reviva Pharmaceuticals Fundamentals Growth
Reviva Stock prices reflect investors' perceptions of the future prospects and financial health of Reviva Pharmaceuticals, and Reviva Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reviva Stock performance.
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 | ||||
| EBITDA | (1.95 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 353.26 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Market Capitalization | 85.81 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
About Reviva Pharmaceuticals Performance
Evaluating Reviva Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Reviva Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Reviva Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.22) | |
| Return On Capital Employed | (2.17) | (2.06) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (2.27) | (2.16) |
Things to note about Reviva Pharmaceuticals performance evaluation
Checking the ongoing alerts about Reviva Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reviva Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Reviva Pharmaceuticals is way too risky over 90 days horizon | |
| Reviva Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Reviva Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Reviva Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Reviva Pharmaceuticals Holdings has accumulated 17.98 M in total debt. Reviva Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Reviva Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reviva Pharmaceuticals Holdings has accumulated about 353.26 K in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com |
- Analyzing Reviva Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reviva Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Reviva Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Reviva Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reviva Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Reviva Pharmaceuticals' stock. These opinions can provide insight into Reviva Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.